EU regulator backs Eli Lilly's Alzheimer's drug after initial rejection

The European Medicines Agency (EMA) has recommended approval for Eli Lilly's Alzheimer's drug, Kisunla, reversing an initial rejection and causing Lilly shares to rise 1.2%. This decision positions Kisunla to become the second disease-modifying Alzheimer's treatment available in Europe, targeting a significant patient population of 6.9 million. However, the approval is restricted to specific patient profiles due to brain swelling risks, and broader adoption, similar to the US experience with Leqembi, may face challenges related to cost and patient eligibility.

Analysis

The European Medicines Agency (EMA) has reversed its initial negative stance and recommended Eli Lilly's (LLY.N) Alzheimer's drug, Kisunla, for approval, causing the company's shares to climb 1.2%. This regulatory green light positions Kisunla to potentially become the second disease-modifying treatment in Europe, targeting a significant market of 6.9 million people that is projected to double by 2050. However, significant commercial hurdles remain. The recommendation is restricted to patients with one or no copy of the ApoE4 gene to mitigate the risk of serious side effects like brain swelling, a concern that led to the initial rejection. This narrows the immediate addressable patient population. Furthermore, the slow U.S. adoption of both Kisunla and its competitor, Leqembi, alongside expert concerns over high costs, suggests that market penetration in cost-conscious European countries may be challenging despite the clinical breakthrough.

Key Decisions for Investors

• Investors in Eli Lilly should view the EMA recommendation as a positive de-risking event for European revenue, but must temper long-term sales forecasts given the restricted patient label and potential for pricing pressure.
• The likely approval of Kisunla introduces direct competition for Biogen's (BIIB.O) Leqembi in Europe, warranting a review of Leqembi's market share and revenue projections in the region.
• Prospective investors in the Alzheimer's drug market should closely monitor reimbursement negotiations and initial adoption rates in Europe, as the slow U.S. rollout highlights significant systemic risks to the commercial viability of this high-cost drug class.